Verastem, Inc. VSTM
$7.55
+3.14%
at last close
Market Cap$683.75 million
P/E Ratio—
Div Yield—
Volume1.73M
52-Week Range
$3.43$11.24
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $13.83 (+83.2% upside)
Key Stats
- Today's Range
- $7.54 – $7.91
- 50-Day Range
- $4.95 – $8.54
- 52-Week Range
- $3.43 – $11.24
- Volume
- 1.73 million shs
- Average Volume
- 2.17 million shs
- Market Cap
- $683.75 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 13.68
- Price / Sales
- 7.81
Short Interest
- Short Interest
- 1.11%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $87.53 million
- Net Income
- $-202,698,000
- Net Margin
- -231.59%
- Return on Equity
- -405.51%
- Debt-to-Equity
- —
About Verastem, Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Related Stocks
Compare head-to-head: VSTM vs LLY·VSTM vs JNJ·VSTM vs ABBV·VSTM vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.